Somchai Chutipongtanate

Dr. Somchai Chutipongtanate

DEPHS, University of Cincinnati, Cincinnati, Ohio, USA
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
WCWararat Chiangjong
Wararat Chiangjong
SCSomchai Chutipongtanate
Somchai Chutipongtanate
SHSuradej Hongeng
Suradej Hongeng
Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist drug action, resulting in increased side effects following drug treatment. A novel therapeutic strategy against cancer cells is the use of anticancer peptides (ACPs). The physicochemical properties, amino acid composition and the addition of chemical groups on the ACP sequence influences their conformation, net charge and orientation of the secondary structure, leading to an effect on targeting specificity and ACP‑cell interaction, as well as peptide penetrating capability, stability and efficacy. ACPs have been developed from both naturally occurring and modified peptides by substituting neutral or anionic amino acid residues with cationic amino acid residues, or by adding a chemical group. The modified peptides lead to an increase in the effectiveness of cancer therapy. Due to this effectiveness, ACPs have recently been improved to form drugs and vaccines, which have sequentially been evaluated in various phases of clinical trials. The development of the ACPs remains focused on generating newly modified ACPs for clinical application in order to decrease the incidence of new cancer cases and decrease the mortality rate. The present review could further facilitate the design of ACPs and increase efficacious ACP therapy in the near future.

1 July 2010 in Analytical Biochemistry
Verified
Journal Article
Closed access
SCSomchai Chutipongtanate
Somchai Chutipongtanate
VTVisith Thongboonkerd
Visith Thongboonkerd

12 April 2021 in Journal of Natural Products
Verified
Journal Article
Closed access
KSKhanit Sa-ngiamsuntorn
Khanit Sa-ngiamsuntorn
ASAmpa Suksatu
Ampa Suksatu
YPYongyut Pewkliang
Yongyut Pewkliang
PTPiyanoot Thongsri
Piyanoot Thongsri
PKPhongthon Kanjanasirirat
Phongthon Kanjanasirirat
SHSuradej Hongeng
Suradej Hongeng

17 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PKPhongthon Kanjanasirirat
Phongthon Kanjanasirirat
ASAmpa Suksatu
Ampa Suksatu
SMSuwimon Manopwisedjaroen
Suwimon Manopwisedjaroen
BMBamroong Munyoo
Bamroong Munyoo
PTPatoomratana Tuchinda
Patoomratana Tuchinda
Arunee ThitithanyanontArunee Thitithanyanont
Arunee Thitithanyanont
Since December 2019, the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused severe pneumonia, a disease named COVID-19, that became pandemic and created an acute threat to public health. The effective therapeutics are in urgent need. Here, we developed a high-content screening for the antiviral candidates using fluorescence-based SARS-CoV-2 nucleoprotein detection in Vero E6 cells coupled with plaque reduction assay. Among 122 Thai natural products, we found that Boesenbergia rotunda extract and its phytochemical compound, panduratin A, exhibited the potent anti-SARS-CoV-2 activity. Treatment with B. rotunda extract and panduratin A after viral infection drastically suppressed SARS-CoV-2 infectivity in Vero E6 cells with IC50 of 3.62 μg/mL (CC50 = 28.06 µg/mL) and 0.81 μΜ (CC50 = 14.71 µM), respectively. Also, the treatment of panduratin A at the pre-entry phase inhibited SARS-CoV-2 infection with IC50 of 5.30 µM (CC50 = 43.47 µM). Our study demonstrated, for the first time, that panduratin A exerts the inhibitory effect against SARS-CoV-2 infection at both pre-entry and post-infection phases. Apart from Vero E6 cells, treatment with this compound was able to suppress viral infectivity in human airway epithelial cells. This result confirmed the potential of panduratin A as the anti-SARS-CoV-2 agent in the major target cells in human. Since B. rotunda is a culinary herb generally grown in China and Southeast Asia, its extract and the purified panduratin A may serve as the promising candidates for therapeutic purposes with economic advantage during COVID-19 situation.

25 November 2005 in Journal of Proteome Research
Verified
Journal Article
Closed access
VTVisith Thongboonkerd
Visith Thongboonkerd
SCSomchai Chutipongtanate
Somchai Chutipongtanate
RKRattiyaporn Kanlaya
Rattiyaporn Kanlaya

1 May 2006 in Clinica Chimica Acta
Verified
Journal Article
Closed access
VTVisith Thongboonkerd
Visith Thongboonkerd
TSTheptida Semangoen
Theptida Semangoen
SCSomchai Chutipongtanate
Somchai Chutipongtanate